Ep. 264 - Prepping for Trump & Alzheimer's Ethics

Trump 2.0 presents opportunities and challenges for leaders of the biopharma industry, which needs effective public policy to thrive. On the latest BioCentury This Week, BioCentury Washington Editor Steve Usdin explains what those opportunities are and lays out the potential impact on the public policy environment, which could have repercussions on FDA and beyond.BioCentury’s editors then analyze how companies, academics and advocates are pushing back on claims that they should have disclosed the results of APOE4 genotype testing to Alzheimer’s trial participants and investigations by Chinese authorities into AstraZeneca China President Leon Wang and fellow AZ employees past and current, assessing what’s known about the allegations and whether the situation could affect other MNCs operating in the country.View full story: https://www.biocentury.com/article/65415700:00 - Introduction01:01 - Prepping for Trump09:41 - Alzheimer's Ethics17:44 - AstraZeneca's Challenges in China21:51 - Myths and MisperceptionsTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text

There are no comments yet.

Please log in to write the first comment.